Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC).
Growth and functional reactivity of lymphocytes obtained from three anatomic compartments in patients with non-small-cell lung cancer (NSCLC).
复制标题
从非小细胞肺癌 (NSCLC) 患者的三个解剖区室获得的淋巴细胞的生长和功能反应性。
DOI：
10.1089/108497803770418283
复制
发表时间：
2003
影响因子：
3.4
通讯作者：
Wroblewski,JoanneM
中科院分区：
文献类型：
--
作者：
Yannelli,JohnR;Hirscowitz,Edward;Wroblewski,JoanneM
非小细胞肺癌（NSCLC）夺去了全世界男性和女性的生命。在这项研究中，我们描述了从 NSCLC 患者的实体瘤活检、胸水和外周血中扩增淋巴细胞的能力。虽然淋巴细胞很容易从固体活检和胸水中扩增，但获得肿瘤特异性淋巴细胞的几率很低。在来自 3/15 实体瘤活检样本 (20%) 和 4 个胸腔液样本中的 2 个样本 (50%) 的肿瘤浸润淋巴细胞 (TIL) 中观察到特异性溶细胞和/或细胞因子释放活性。源自实体瘤的两种 CTL 具有溶细胞性，一种是 HLA-A2 限制性的，另一种是 HLA-A30 或 -B18 限制性的。其中一种胸水细胞毒性T淋巴细胞(CTL)也受到HLA-A2限制。如先前报道，使用混合淋巴细胞肿瘤细胞培养物 (MLTC) 对 NSCLC 患者的外周血进行了研究。用同种异体NSCLC-TC系29.7培养外周血淋巴细胞，该系通过基因转移表达淋巴细胞共刺激分子CD80。在测试的 9 个 HLA-A2 患者样本中，有 8 个产生了淋巴细胞，它们以主要组织相容性复合物 (MHC) 限制的方式裂解表达 HLA-A2 的 NSCLC 肿瘤细胞。虽然特定的 CTL 可以从所有解剖部位产生，但对于临床试验来说，外周血似乎是获得特定前体的选择部位。
Non–small-cell lung cancer (NSCLC) claims the lives of both men and women worldwide. In this study, we describe the ability to expand lymphocytes from solid tumor biopsies, pleural fluid, and peripheral blood of patients with NSCLC. While lymphocytes readily expanded from both solid biopsies and pleural fluids, the incidence of obtaining tumor-specific lymphocytes was low. Specific cytolytic and/or cytokine-releasing activity was observed in tumor-infiltrating lymphocytes (TIL) from 3/15 solid tumor biopsies (20%) and 2 of 4 pleural fluid samples (50%). Two of the CTL derived from solid tumor were cytolytic, one being HLA-A2 restricted while the other was either restricted at HLA-A30 or - B18. One of the pleural fluid cytotoxic T lymphocyte (CTL) was also HLA-A2 restricted. Peripheral blood from NSCLC patients was studied using mixed lymphocyte tumor cell cultures (MLTC) as reported previously. Peripheral blood lymphocytes were cultured with allogeneic NSCLC-TC line 29.7, which expressed by gene transfer the lymphocyte costimulatory molecule CD80. Of 9 HLA-A2 patient samples tested, 8 gave rise to lymphocytes, which lysed NSCLC tumor cells expressing HLA-A2 in an major histocompatibility complex (MHC)–restricted fashion. While specific CTL can be generated from all anatomic sites, for clinical trials peripheral blood appears to be the site of choice for obtaining specific precursors.